FOLH1 and prostate carcinoma: Currently, several reporting guidelines have been suggested (Prostate Cancer Molecular Imaging Standardized Evaluation [PROMISE], Prostate-specific Membrane Antigen Reporting and Data System [PSMA-RADS], European Association of Nuclear Medicine-Prostate-Specific Membrane Antigen [E-PSMA]), which vary in reporting details; however, none are utilized in the community practice setting (Supplemental Table 3) [2, 34, 35].